In additions, there was a trend that patients with IDH1-R132H and ATRX loss grade II/III gliomas had longer PFS than patients with IDH1-R132H and ATRX positive grade II/III gliomas and PFS of patients with GBM was similar to that of patients with IDH wild type (Figure 5F). This evidence concerns the gene IDH2 and glioma.